LY3375880

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Atopic DermatitisHealthy

Phase 1

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

CompletedNCT03913260

Eli Lilly and CompanyHealthy

Start: 2019-05-01End: 2019-09-19Updated: 2019-10-11

Phase 2

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT03831191

Eli Lilly and CompanyAtopic Dermatitis

Start: 2019-02-12End: 2020-02-27Updated: 2021-04-20